J P Pignon

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint Meta-analyses of randomised clinical trials in oncology
    J P Pignon
    Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 2:475-82. 2001
  2. doi request reprint Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients
    Jean Pierre Pignon
    Department of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif, France
    Radiother Oncol 92:4-14. 2009
  3. pmc Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data
    Audrey Mauguen
    Meta analysis Unit, Department of Biostatistics and Epidemiology, Gustave Roussy Institute, Villejuif, France
    Lancet Oncol 14:619-26. 2013
  4. doi request reprint Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group
    Pierre Blanchard
    Institut Gustave Roussy, Villejuif Cedex, France
    J Clin Oncol 31:2854-60. 2013
  5. doi request reprint Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis
    Audrey Mauguen
    Institut de Cance rologie Gustave Roussy, Villejuif, France
    J Clin Oncol 30:2788-97. 2012
  6. pmc Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival
    Lucie Oberic
    Institut Gustave Roussy, Villejuif, France
    Radiat Oncol 6:124. 2011
  7. ncbi request reprint [Meta-analyses on individual patient data and treatment evaluation in oncology]
    Jean Pierre Pignon
    Service de biostatistique et d épidémiologie, Institut Gustave Roussy, 94805 Villejuif Cedex
    Bull Cancer 94:957-64. 2007
  8. ncbi request reprint [Individual patient data meta-analyses in head and neck carcinoma: what have we learnt?]
    J P Pignon
    Service de biostatistique et d épidémiologie, Département de Chirurgie Cervicofaciale, Departement de Radiotherapie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Cancer Radiother 9:31-6. 2005
  9. doi request reprint Role of meta-analyses and of large randomized trials in the study of cancer treatments
    Jean Pierre Pignon
    Service de biostatistique et d épidémiologie, Institut Gustave Roussy, Villejuif cedex 95805, France
    Lung Cancer 65:9-12. 2009
  10. ncbi request reprint Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer
    J P Pignon
    Department of Biostatistics and Epidemiology, Institut Gustav Roussy, Villejuif, France
    Lancet 355:949-55. 2000

Detail Information

Publications66

  1. ncbi request reprint Meta-analyses of randomised clinical trials in oncology
    J P Pignon
    Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 2:475-82. 2001
    ..The main factors which influence the quality of a meta-analysis are discussed...
  2. doi request reprint Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients
    Jean Pierre Pignon
    Department of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif, France
    Radiother Oncol 92:4-14. 2009
    ..However the heterogeneity of the results limited the conclusions and prompted us to confirm the results on a more complete database by adding the randomised trials conducted between 1994 and 2000...
  3. pmc Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data
    Audrey Mauguen
    Meta analysis Unit, Department of Biostatistics and Epidemiology, Gustave Roussy Institute, Villejuif, France
    Lancet Oncol 14:619-26. 2013
    ..Surrogate endpoints that would enable earlier assessments of treatment effects would be useful. We assessed the correlations between potential surrogate endpoints and overall survival at individual and trial levels...
  4. doi request reprint Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group
    Pierre Blanchard
    Institut Gustave Roussy, Villejuif Cedex, France
    J Clin Oncol 31:2854-60. 2013
    ..007), and 0.63 (95% CI, 0.45 to 0.89; P = .009) respectively. CONCLUSION This IPD meta-analysis shows the superiority of Tax-PF over PF as induction chemotherapy. Its precise role in the management of LAHNC remains to be determined. ..
  5. doi request reprint Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis
    Audrey Mauguen
    Institut de Cance rologie Gustave Roussy, Villejuif, France
    J Clin Oncol 30:2788-97. 2012
    ..The Meta-Analysis of Radiotherapy in Lung Cancer Collaborative Group decided to address the role of modified radiotherapy fractionation...
  6. pmc Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival
    Lucie Oberic
    Institut Gustave Roussy, Villejuif, France
    Radiat Oncol 6:124. 2011
    ..We report here the results of the docetaxel plus 5 FU regimen stopped according to the interim analysis. The docetaxel plus cisplatin arm was continued...
  7. ncbi request reprint [Meta-analyses on individual patient data and treatment evaluation in oncology]
    Jean Pierre Pignon
    Service de biostatistique et d épidémiologie, Institut Gustave Roussy, 94805 Villejuif Cedex
    Bull Cancer 94:957-64. 2007
    ..Lastly, the large data bases of individual patient data meta-analyses allow subsidiary studies such as validation studies of surrogate endpoints or studies of the predictive value of tumour markers...
  8. ncbi request reprint [Individual patient data meta-analyses in head and neck carcinoma: what have we learnt?]
    J P Pignon
    Service de biostatistique et d épidémiologie, Département de Chirurgie Cervicofaciale, Departement de Radiotherapie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Cancer Radiother 9:31-6. 2005
    ..The results showed a small but significant improvement in favor of altered fractionated RT for overall survival and local control with an absolute benefit at five years of 3 and 6%, respectively...
  9. doi request reprint Role of meta-analyses and of large randomized trials in the study of cancer treatments
    Jean Pierre Pignon
    Service de biostatistique et d épidémiologie, Institut Gustave Roussy, Villejuif cedex 95805, France
    Lung Cancer 65:9-12. 2009
    ..In conclusion, well-conducted meta-analyses and large trials are complementary tools to evaluate new treatments...
  10. ncbi request reprint Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer
    J P Pignon
    Department of Biostatistics and Epidemiology, Institut Gustav Roussy, Villejuif, France
    Lancet 355:949-55. 2000
    ..We did three meta-analyses of the impact of survival on chemotherapy added to locoregional treatment...
  11. doi request reprint Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group
    Jean Pierre Pignon
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    J Clin Oncol 26:3552-9. 2008
    ..The aim of the Lung Adjuvant Cisplatin Evaluation was to identify treatment options associated with a higher benefit or groups of patients who particularly benefit from postoperative chemotherapy...
  12. ncbi request reprint Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update
    Jean Pierre Pignon
    Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 69:S112-4. 2007
  13. ncbi request reprint Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck
    Jean Pierre Pignon
    Unit of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif, France
    Anticancer Drugs 15:331-40. 2004
    ..We conclude that this improved survival might be due either to docetaxel's pharmacologic effect or to uncontrolled prognostic factors...
  14. doi request reprint Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial
    J Pénichoux
    Biostatistics and Epidemiology Unit, Institut de Cancerologie Gustave Roussy, Villejuif, France
    Eur J Cancer 49:1882-8. 2013
    ..7 [1.4-2.1]). Overall, this study suggests that starting with less toxic first-line treatment is a valid option since it does not exert a deleterious effect on the risk of overall progression or death...
  15. ncbi request reprint [Larynx preservation: nonsurgical approaches]
    J Bourhis
    Departement de Radiotherapie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Cancer Radiother 8:S24-8. 2004
    ..Finally, larynx preservation is generally not proposed in patients with deeply infiltrating tumors and or tumor invading the cartilage or soft tissue in the neck (T4)...
  16. doi request reprint Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
    M Ducreux
    Department of Medicine, Institut Gustave Roussy, Villejuif, Universite Paris Sud, Le Kremlin Bicetre, France
    Eur J Cancer 49:1236-45. 2013
    ....
  17. ncbi request reprint A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma
    M Ducreux
    Institut Gustave Roussy, Service d Oncologie Digestive, Villejuif, France
    Ann Oncol 13:1185-91. 2002
    ..5% response rate and a 29% survival rate at 1 year. The present study aimed to compare FUP with 5-FU alone, which was the control arm in former Mayo Clinic trials...
  18. ncbi request reprint Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications
    F Andre
    Departments of Medicine and Biostatistics, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 18:2981-9. 2000
    ..We analyzed the prognosis of patients with resected N2 NSCLC to propose homogeneous patient subgroups...
  19. ncbi request reprint Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases
    D Elias
    Department of Oncologic Surgery, Institut Gustave Roussy, Comprehensive Cancer Centre, Villejuif, France
    J Surg Oncol 69:88-93. 1998
    ..The true impact of the width of the margin on the prognosis is unclear...
  20. pmc Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial
    V Boige
    Gastrointestinal Oncology Unit, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 97:862-7. 2007
    ..However, the manageable toxicity profile and the encouraging disease control rate deserve further attention for this convenient, outpatient-based chemotherapy regimen...
  21. ncbi request reprint [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial]
    C Locher
    , Institut Gustave-Roussy, Villejuif, France
    Gastroenterol Clin Biol 25:749-54. 2001
    ..In this study, toxicity was probably overestimated due to the small number of patients. More patients are necessary in order to better estimate the cost of toxicity of these chemotherapies...
  22. ncbi request reprint Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases
    D Elias
    Department of Surgical Oncology, Institut Gustave Roussy, Villejuif, France
    Br J Surg 90:567-74. 2003
    ..The present study reports the long-term outcome and prognostic factors of patients undergoing resection of extrahepatic disease simultaneously with hepatectomy for liver metastases...
  23. ncbi request reprint Random effects survival models gave a better understanding of heterogeneity in individual patient data meta-analyses
    S Michiels
    Department of Biostatistics and Epidemiology, Institut Gustave Roussy, 39, rue Camille Desmoulins 94805 Villejuif Cedex, France
    J Clin Epidemiol 58:238-45. 2005
    ..One way to investigate and accommodate this heterogeneity is to use models that include random effects...
  24. ncbi request reprint [Adjuvant chemotherapy in non-small cell lung cancer]
    Laurent Taillade
    Comité de pathologie thoracique, Institut Gustave Roussy, Villejuif, France
    Bull Cancer 91:63-7. 2004
    ..In this article, the current status of adjuvant chemotherapy is reviewed, and future prospects are discussed...
  25. ncbi request reprint Nasopharyngeal carcinoma and therapeutic management: the place of chemotherapy
    J Guigay
    Department of Medical Oncology, Institut de Cancerologie Gustave Roussy, Villejuif, France
    Ann Oncol 17:x304-7. 2006
  26. doi request reprint Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601
    F Ferrand
    Institut Gustave Roussy, Gastro Intestinal Unit, Department of Oncologic Medicine, Universite Paris Sud, Villejuif, France
    Eur J Cancer 49:90-7. 2013
    ..To assess the impact of primary tumour resection on overall survival (OS) of patients diagnosed with stage IV colorectal cancer (CRC)...
  27. ncbi request reprint Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial
    M Ducreux
    Institut Gustave Roussy, Villejuif, France
    Oncology 70:222-30. 2006
    ....
  28. ncbi request reprint Randomized trials of amifostine and radiotherapy: effect on survival?
    J Bourhis
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, Cedex France
    Semin Oncol 31:62-6. 2004
    ..It will be also possible to study the effect(s) of amifostine in different tumor types...
  29. ncbi request reprint Meta-analyses in head and neck squamous cell carcinoma. What is the role of chemotherapy?
    J Bourhis
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
    Hematol Oncol Clin North Am 13:769-75, vii. 1999
    ....
  30. pmc Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis
    F Janot
    Department of Head and Neck Surgery, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 73:531-8. 1996
    ..All the other histological and biological factors studied failed to provide further prognostic information. These findings may help to select patients with high metastatic risk...
  31. doi request reprint Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
    J C Soria
    Department of Medicine, Institut Gustave Roussy, INSERM Unit 981 and Paris University XI, Villejuif, France
    Ann Oncol 24:20-30. 2013
    ..Previous studies have demonstrated the efficacy and safety of bevacizumab in the treatment of non-small-cell lung cancer (NSCLC)...
  32. doi request reprint Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
    I Borget
    Etudes et Recherche en Economie de la Santé, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur Respir J 39:172-9. 2012
    ..Sensitivity analyses confirmed the robustness of the results. The cost-effectiveness of second-line NSCLC treatment is improved when patients are selected on either clinical or biological grounds...
  33. ncbi request reprint Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients
    A Auperin
    Unit of Biostatistics and Epidemiology, Radiation Oncology and Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 17:473-83. 2006
    ..Despite several randomised trials comparing radiotherapy alone with concomitant radio-chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC), it is not clear whether the addition of chemotherapy improves survival...
  34. ncbi request reprint Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
    A Italiano
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Ann Oncol 19:787-92. 2008
    ..There is scarce data concerning outcome and survival of patients enrolled in current phase I oncology trials...
  35. doi request reprint Immunogenic death of colon cancer cells treated with oxaliplatin
    A Tesniere
    INSERM, U848, Villejuif, France
    Oncogene 29:482-91. 2010
    ..In conclusion, OXP induces immunogenic death of CRC cells, and this effect determines its therapeutic efficacy in CRC patients...
  36. ncbi request reprint Chemo-radiotherapy in head and neck cancer
    J Bourhis
    Department of Radiation Oncology, Gustave Roussy Institute, Villejuif, France
    Ann Oncol 17:x39-41. 2006
  37. ncbi request reprint Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial
    Isabelle Borget
    Gustave Roussy Institute, Villejuif, France
    Oncology 71:40-8. 2006
    ..The aim of the study was to evaluate the efficacy and the costs of three regimens as compared to HD-LV5FU2: raltitrexed (R), LV5FU2 with a lower dose of folinic acid (LD-LV5FU2), and weekly infusional 5FU (WI-FU)...
  38. ncbi request reprint Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data
    Karim Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 8:994-1000. 2007
    ..We aimed to assess whether combining estramustine with chemotherapy increases survival in patients with castration-refractory prostate cancer...
  39. ncbi request reprint Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis
    Julien Domont
    Institut Gustave Roussy, Division of Cancer Médecine, 39 rue Camille Desmoulins, 94805 Villejuif, France
    J Clin Oncol 23:3086-93. 2005
    ..To determine the role of the catalytic subunit of human telomerase reverse transcriptase (hTERT) in predicting survival after resection of hepatic colorectal metastases (CRM)...
  40. ncbi request reprint Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect
    Dominique Elias
    Department of Surgical Oncology, Institut Gustave Roussy, Comprehensive Cancer Center, 39 rue Camille Desmoulins, Villejuif Cedex, 94805, France
    Ann Surg Oncol 12:900-9. 2005
    ..After resection, the prognosis is based more on the total number of resected metastases (located inside and outside the liver) than on the site of these metastases (only inside the liver or not)...
  41. ncbi request reprint Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients
    Bertrand Baujat
    Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 64:47-56. 2006
    ..To study the effect of adding chemotherapy to radiotherapy (RT) on overall survival and event-free survival for patients with nasopharyngeal carcinoma...
  42. ncbi request reprint Should adjuvant chemotherapy become standard treatment in all patients with resected non-small-cell lung cancer?
    Thierry Le Chevalier
    Institut Gustave Roussy, Faculte de Medecine Paris Sud, 94800 Villejuif, France
    Lancet Oncol 6:182-4. 2005
    ..In this debate, Thierry Le Chevalier and colleagues and Giorgio Scagliotti present opposing arguments for whether this approach should be considered standard...
  43. ncbi request reprint [Colorectal cancer: prognostic molecular markers]
    Valerie Boige
    Unité de Gastro Entérologie, Institut Gustave Roussy, Villejuif
    Gastroenterol Clin Biol 28:21-32. 2004
  44. ncbi request reprint Meta-analysis when only the median survival times are known: a comparison with individual patient data results
    Stefan Michiels
    Department of Public Health, Institut Gustave Roussy, Villejuif Cedex, France
    Int J Technol Assess Health Care 21:119-25. 2005
    ..We aimed to evaluate retrospectively the performance of meta-analyses using median survival times and survival rates by comparing them with meta-analyses using IPD to calculate HRs...
  45. ncbi request reprint Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis
    Catherine Delbaldo
    Department of Medecine, Institut Gustave Roussy, Villejuif Cedex, France
    JAMA 292:470-84. 2004
    ....
  46. ncbi request reprint Results of R0 resection for colorectal liver metastases associated with extrahepatic disease
    Dominique Elias
    Department of Surgical Oncology, Gustave Roussy Institute, Villejuif, France
    Ann Surg Oncol 11:274-80. 2004
    ..This study reports the long-term outcome and prognostic factors of patients undergoing extrahepatic disease resection simultaneously with hepatectomy for liver metastases...
  47. ncbi request reprint Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial
    Ariane Dunant
    Department of Biostatistics and Epidemiology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Clin Cancer Res 11:5017s-5021s. 2005
    ....
  48. ncbi request reprint Individual patients' data meta-analyses in head and neck cancer
    Jean Bourhis
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
    Curr Opin Oncol 19:188-94. 2007
    ..The database included nearly 120 randomized trials, and about 25,000 patients, with a median follow-up of 6 years...
  49. ncbi request reprint Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
    Jean Bourhis
    Radiation Oncology Department, Institut Gustave Roussy, Villejuif, France
    Lancet 368:843-54. 2006
    ..The aim of this meta-analysis was to assess whether this type of radiotherapy could improve survival...
  50. doi request reprint Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial
    E Deutsch
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif
    Ann Oncol 24:2834-8. 2013
    ..The ACCORD 16 phase II trial aimed to evaluate the objective response rate after combination of conventional chemoradiotherapy (CRT) and cetuximab in locally advanced anal canal carcinoma (LAACC)...
  51. ncbi request reprint [Estimation of alcohol-related deaths in France in 1985]
    J P Pignon
    , Institut Gustave Roussy, Villejuif
    Gastroenterol Clin Biol 15:51-6. 1991
    ....
  52. ncbi request reprint A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials
    Bertrand Baujat
    Institut Gustave Roussy, Département de Biostatistique et d Epidémiologie, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Stat Med 21:2641-52. 2002
    ..This method can also be applied to identify types of patients that explain heterogeneity in the treatment effect...
  53. ncbi request reprint Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution
    D Elias
    Department of Surgical Oncology, Institut Gustave Roussy Comprehensive Cancer Center, Villejuif, France
    Ann Oncol 13:267-72. 2002
    ..Oxaliplatin has demonstrated significant activity in advanced colorectal cancer, and this is the first publication concerning its intraperitoneal administration...
  54. doi request reprint Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data
    Jean Bourhis
    Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France
    J Clin Oncol 29:2590-7. 2011
    ..The aim of this meta-analysis was to evaluate the impact of amifostine on overall survival (OS) and progression-free survival (PFS) in patients treated with radiotherapy or chemoradiotherapy...
  55. ncbi request reprint Chemotherapy in non-small cell lung cancer: an update of an individual patient data-based meta-analysis
    Sarah Burdett
    J Thorac Cardiovasc Surg 129:1205; author reply 1205-6. 2005
  56. ncbi request reprint Resected non-small cell lung cancer: need for adjuvant lymph node treatment? From hope to reality
    Rodrigo Arriagada
    Instituto de Radiomedicina IRAM, Américo Vespucio Norte 1314, Vitacura, Santiago, Chile
    Lung Cancer 42:S57-64. 2003
    ..We discuss here the available worldwide information on this subject. There is an urgent need for new trials in this topic...
  57. ncbi request reprint Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
    Rodrigo Arriagada
    Instituto de Radiomedicina, Santiago, Chile
    N Engl J Med 350:351-60. 2004
    ..On the basis of a previous meta-analysis, the International Adjuvant Lung Cancer Trial was designed to evaluate the effect of cisplatin-based adjuvant chemotherapy on survival after complete resection of non-small-cell lung cancer...
  58. ncbi request reprint Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement
    Cécile Le Péchoux
    J Clin Oncol 25:e10-1. 2007
  59. ncbi request reprint Letter to the editor
    Sarah Burdett
    Lung Cancer 48:149-50. 2005
  60. ncbi request reprint Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program
    Martin Filipits
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    J Clin Oncol 25:2735-40. 2007
    ..The purpose of our study was to determine whether cell cycle regulators are of prognostic and/or predictive value in patients who were enrolled onto the IALT...
  61. ncbi request reprint Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program
    Martin Filipits
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Clin Cancer Res 13:3892-8. 2007
    ..The purpose of our study was to determine whether multidrug resistance proteins (MRP) are of prognostic and/or predictive value in patients who were enrolled into the International Adjuvant Lung Cancer Trial (IALT)...
  62. ncbi request reprint Comment on "Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature" by T. Berghmans, M. Paesmans, A.P. Meert, C. Mascaux, P. Lothaire, J.J. Lafitte, et al. [Lun
    Jean Pierre Pignon
    Lung Cancer 51:261-2; author reply 263-5. 2006
  63. doi request reprint Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer
    Martin Fruh
    Department of Medical Oncology, Princess Margaret Hospital, Toronto
    J Clin Oncol 26:3573-81. 2008
    ..This pooled analysis was undertaken to assess the efficacy and toxicity of adjuvant cisplatin-based chemotherapy in elderly patients with non-small-cell lung cancer (NSCLC)...
  64. ncbi request reprint DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    Ken A Olaussen
    Laboratory of Radiobiology and Oncology, Commissariat a l Energie Atomique, Fontenay aux Roses, University of Paris 11, Paris, France
    N Engl J Med 355:983-91. 2006
    ..Adjuvant cisplatin-based chemotherapy improves survival among patients with completely resected non-small-cell lung cancer, but there is no validated clinical or biologic predictor of the benefit of chemotherapy...
  65. ncbi request reprint Chemotherapy in non-small-cell lung cancer: an update of an individual patient data meta-analysis
    Sarah Burdett
    J Clin Oncol 23:924-5; author reply 925-6. 2005
  66. ncbi request reprint Progression-free survival is a surrogate for survival in advanced colorectal cancer
    Marc Buyse
    International Drug Development Institute, Louvain la Neuve, Belgium
    J Clin Oncol 25:5218-24. 2007
    ..We investigated whether progression-free survival (PFS) could be considered a valid surrogate for OS in advanced colorectal cancer...